| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8933097 | CHATTEM SANOFI | Fexofenadine suspension formulation |
Aug, 2030
(6 years from now) | |
Children'S Allegra Allergy is owned by Chattem Sanofi.
Children'S Allegra Allergy contains Fexofenadine Hydrochloride.
Children'S Allegra Allergy has a total of 1 drug patent out of which 0 drug patents have expired.
Children'S Allegra Allergy was authorised for market use on 24 January, 2011.
Children'S Allegra Allergy is available in suspension;oral dosage forms.
The generics of Children'S Allegra Allergy are possible to be released after 02 August, 2030.
Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2011
Treatment: NA
Dosage: SUSPENSION;ORAL
CHILDREN'S ALLEGRA ALLERGY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic